公开(公告)号：EP4420673A3

公开(公告)日：2024-11-06

申请号：EP24169078.3

申请日：2020-08-03

申请人： Bioversys AG

发明人： DALE, Glenn, E. ,  LOCIURO, Sergio ,  KEMMER, Christian ,  TREBOSC, Vincent ,  GITZINGER, Marc

IPC分类号： A61K9/08 ,  A61K9/00 ,  A61K47/26 ,  A61K47/10 ,  A61K47/12 ,  A61K31/438 ,  A61K47/22 ,  A61K47/18 ,  A61K47/02 ,  A61K47/20 ,  A61P31/04 ,  A61P31/06 ,  A61K31/546 ,  A61K38/12

摘要： The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or C max . The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a C max is that greater than about 2 mg/L and optionally less than about 50 mg/L.

公开(公告)号：EP3955930B1

公开(公告)日：2024-11-06

申请号：EP20791696.6

申请日：2020-04-14

发明人： KLAUSNER, Jeffrey D.

IPC分类号： A61K31/546 ,  C07K14/22

公开(公告)号：EP4384153A1

公开(公告)日：2024-06-19

申请号：EP22856320.1

申请日：2022-08-11

申请人： Evithe Limited

发明人： HUNEFELD-GAIKEMA, Cynthia

IPC分类号： A61K31/12 ,  A61K31/546 ,  A61K31/7036 ,  A61K9/00 ,  C07C45/78 ,  C07C49/255 ,  C11B9/02 ,  A61K36/9068 ,  A61K38/14 ,  A61P31/04 ,  A61P31/10

CPC分类号： A23L33/105 ,  C07C45/673 ,  A61K36/9068 ,  A61K2236/1020130101 ,  A61K2236/3020130101 ,  A61K2236/33320130101 ,  A61K45/06 ,  A61K31/7036 ,  A61K31/12 ,  A61K38/14 ,  A61P31/04 ,  A61K31/546 ,  Y02A50/30

公开(公告)号：EP4340844A1

公开(公告)日：2024-03-27

申请号：EP22729717.3

申请日：2022-05-20

申请人： Fondazione Telethon ETS ,  Università degli Studi di Perugia ,  Università Degli Studi Di Trento

发明人： BIASINI, Emiliano ,  BARRECA, Maria Letizia ,  MANFRONI, Giuseppe ,  FALLARINO, Francesca

IPC分类号： A61K31/5415 ,  A61K31/542 ,  A61K31/546 ,  A61K45/06 ,  A61P25/08 ,  C07D279/02 ,  C07D417/12 ,  C07D513/04

公开(公告)号：EP3785718B1

公开(公告)日：2024-03-27

申请号：EP19792006.9

申请日：2019-04-24

发明人： WON, Cheol Hee ,  MIN, Dal Hee

IPC分类号： A61K31/7036 ,  A61K31/7008 ,  A61K31/47 ,  A61P31/14 ,  A61K31/282 ,  A61K31/402 ,  A61K31/422 ,  A61K31/496 ,  A61K31/536 ,  A61K31/5415 ,  A61K31/546 ,  A61K31/555 ,  A61K31/685 ,  A61K31/4706 ,  A61K31/7048 ,  A61K38/12 ,  A61K38/14

公开(公告)号：EP2970369B1

公开(公告)日：2023-11-22

申请号：EP14769286.7

申请日：2014-03-14

发明人： SCHENTAG, Jerome, J. ,  McCourt, Mary, P. ,  MIELNICKI, Lawrence ,  HUGHES, Julie

IPC分类号： A61K9/127 ,  A61K38/14 ,  A61K31/12 ,  A61K38/28 ,  A61K31/137 ,  A61K31/19 ,  A61K31/546 ,  A61K31/7034 ,  A61K31/713 ,  A61P3/06 ,  A61P3/10 ,  A61P5/06 ,  A61P11/06 ,  A61P5/50 ,  A61P9/12 ,  A61P31/04 ,  A61P31/12 ,  A61P31/14 ,  A61P35/00

公开(公告)号：EP3919059B1

公开(公告)日：2023-11-01

申请号：EP20766484.8

申请日：2020-02-20

发明人： SUN, Tianyu

IPC分类号： A61K31/43 ,  A61K31/546 ,  A61K31/545 ,  A61K31/54 ,  A61P31/04 ,  A61P31/00

公开(公告)号：EP4218766A1

公开(公告)日：2023-08-02

申请号：EP23157487.2

申请日：2015-04-22

申请人： Incyte Holdings Corporation

发明人： COMBS, Andrew, P. ,  MADUSKUIE, Thomas, P., Jr. ,  FALAHATPISHEH, Nikoo

IPC分类号： A61K31/546 ,  C07D471/04 ,  A61P35/00

摘要： The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

公开(公告)号：EP4190332A1

公开(公告)日：2023-06-07

申请号：EP21850852.1

申请日：2021-07-28

申请人： Shionogi & Co., Ltd

发明人： KAWASAKI Hidenori ,  ITO Masaaki

IPC分类号： A61K31/546 ,  A61K9/19 ,  A61K47/02 ,  A61K47/26 ,  A61P31/04

摘要： The present invention relates to a method for manufacturing a lyophilized formulation which comprises a compound represented by Formula (I):

or its pharmaceutically acceptable salt, wherein the water content is controlled and the reconstitution time is short; and a lyophilized formulation.
With a method for manufacturing a lyophilized formulation comprising at least the following steps:
1) a step of cooling a liquid comprising the compound represented by Formula (I) or its pharmaceutically acceptable salt in a chamber of a lyophilizer to a predetermined cooling temperature, and
2) a step of introducing ice crystals into the chamber,
and a lyophilized formulation having a specific surface area of 0.6 to 1.1 m 2 /g, the water content can be 0.5% or less, and the reconstitution time can be 30 seconds or less.

公开(公告)号：EP4074315A1

公开(公告)日：2022-10-19

申请号：EP22176241.2

申请日：2019-04-23

申请人： Korea Institute of Radiological & Medical Sciences

发明人： LIM, Young Bin ,  PARK, Myung Jin ,  LEE, Hyoun Ji

IPC分类号： A61K31/546 ,  A61K31/4515 ,  A61K31/496 ,  A61P43/00 ,  A23L33/10 ,  A61K31/5415 ,  A61P35/00 ,  A61K45/06

摘要： The present invention relates to a composition for enhancing radiation sensitivity comprising aripiprazole as an active ingredient, and more specifically, to a composition for enhancing radiation sensitivity capable of treating cancer by acting as a radiation sensitizer when aripiprazole is combined with radiation. By administering an effective amount of aripiprazole according to the present invention in combination with radiation irradiation, it has excellent radiation sensitivity enhancing effects such as reducing cancer cell viability and inducing cancer cell death, so it can be usefully used as a radiation sensitivity enhancer.